Molecular diagnostics as a tool to personalize treatment in adult glioma patients

被引:15
作者
Jeuken, Judith W. M. [1 ]
van der Maazen, Richard W. M.
Wesseling, Pieter
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NCMLS, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, NCMLS, Nijmegen, Netherlands
关键词
glioma; astrocytoma; oligodendroglioma; glioblastoma; molecular diagnostics;
D O I
10.1177/153303460600500305
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gliomas, the most frequent primary brain tumors in humans, form a heterogeneous group, encompassing many different histological types and malignancy grades. Within this group, the diffuse infiltrative gliomas are by far the most common in adults. The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors. Especially in these diffuse gliomas, the role of molecular diagnostics is rapidly increasing. After summarizing the most relevant genetic aberrations and pathways in these tumors detected up till now, this review will discuss the clinical relevance of this information. Several molecular markers have been identified in diffuse gliomas that carry diagnostic and prognostic information. In addition, some of these and other markers predict the response of these gliomas to particular (chemo)therapeutic approaches. The techniques used to obtain this molecular information, as well as the advantages and disadvantages of the different techniques will be discussed. Finally, future perspectives will be presented with regard to the contribution of molecular diagnostics to tailor-made therapy in glioma patients.
引用
收藏
页码:215 / 229
页数:15
相关论文
共 95 条
[1]  
Afra D, 2002, LANCET, V359, P1011
[2]  
BASELGA J, 2002, ONCOL BIOTHERAPEUTIC, V2, P36
[3]   Mutation analysis of B-RAF gene in human gliomas [J].
Basto, D ;
Trovisco, V ;
Lopes, JM ;
Martins, A ;
Pardal, F ;
Soares, P ;
Reis, RM .
ACTA NEUROPATHOLOGICA, 2005, 109 (02) :207-210
[4]  
BELLO MJ, 1995, INT J CANCER, V64, P207
[5]   MOLECULAR ANALYSIS OF CHROMOSOME-1 ABNORMALITIES IN HUMAN GLIOMAS REVEALS FREQUENT LOSS OF 1P IN OLIGODENDROGLIAL TUMORS [J].
BELLO, MJ ;
VAQUERO, J ;
DECAMPOS, JM ;
KUSAK, ME ;
SARASA, JL ;
SAEZCASTRESANA, J ;
PESTANA, A ;
REY, JA .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (02) :172-175
[6]   Clinical anticancer drug development: targeting the cyclin-dependent kinases [J].
Benson, C ;
Kaye, S ;
Workman, P ;
Garrett, M ;
Walton, M ;
de Bono, J .
BRITISH JOURNAL OF CANCER, 2005, 92 (01) :7-12
[7]   Amplification and overexpression of MDM2 in primary (de novo) glioblastomas [J].
Biernat, W ;
Kleihues, P ;
Yonekawa, Y ;
Ohgaki, H .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (02) :180-185
[8]   Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization [J].
Bigner, SH ;
Matthews, MR ;
Rasheed, BKA ;
Wiltshire, RN ;
Friedman, HS ;
Friedman, AH ;
Stenzel, TT ;
Dawes, DM ;
McLendon, RE ;
Bigner, DD .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) :375-386
[9]   Association of chromosome 10 losses and negative prognosis in oligoastrocytomas [J].
Bissola, L ;
Eoli, M ;
Pollo, B ;
Merciai, BM ;
Silvani, A ;
Salsano, E ;
Maccagnano, C ;
Bruzzone, MG ;
Conti, AMF ;
Solero, CL ;
Giombini, S ;
Broggi, G ;
Boiardi, A ;
Finocchiaro, G .
ANNALS OF NEUROLOGY, 2002, 52 (06) :842-845
[10]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479